Alex Mercer

2.2k total citations
32 papers, 1.1k citations indexed

About

Alex Mercer is a scholar working on Nephrology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alex Mercer has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Nephrology, 4 papers in Pathology and Forensic Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alex Mercer's work include Renal Diseases and Glomerulopathies (18 papers), Chronic Kidney Disease and Diabetes (7 papers) and Neurogenesis and neuroplasticity mechanisms (4 papers). Alex Mercer is often cited by papers focused on Renal Diseases and Glomerulopathies (18 papers), Chronic Kidney Disease and Diabetes (7 papers) and Neurogenesis and neuroplasticity mechanisms (4 papers). Alex Mercer collaborates with scholars based in United States, United Kingdom and Italy. Alex Mercer's co-authors include Olof Zachrisson, Cesare Patrone, Harriet Rönnholm, Jonathan Barratt, Lilian Wikström, Karin Dannaeus, Annica Andersson, Elisabet I. Nielsen, Jürgen Floege and Jarkko Kortesmaa and has published in prestigious journals such as The Lancet, Journal of the American Society of Nephrology and American Journal of Kidney Diseases.

In The Last Decade

Alex Mercer

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alex Mercer United States 12 579 205 195 193 191 32 1.1k
Denis Morin France 18 385 0.7× 145 0.7× 54 0.3× 54 0.3× 127 0.7× 51 1.4k
Susan Ritchie United States 19 557 1.0× 53 0.3× 124 0.6× 62 0.3× 174 0.9× 32 1.8k
Alison Skrinar United States 21 691 1.2× 37 0.2× 118 0.6× 19 0.1× 97 0.5× 50 1.5k
Gary Milligan United Kingdom 18 46 0.1× 158 0.8× 155 0.8× 44 0.2× 127 0.7× 72 1.5k
Cheng-Chun Lee Taiwan 23 50 0.1× 59 0.3× 178 0.9× 51 0.3× 112 0.6× 53 1.2k
Stephanie Krämer Germany 20 219 0.4× 40 0.2× 60 0.3× 12 0.1× 200 1.0× 38 1.2k
Janet Y. Lee United States 12 112 0.2× 25 0.1× 169 0.9× 75 0.4× 39 0.2× 21 948
Jia‐Shu Chen United States 18 79 0.1× 17 0.1× 58 0.3× 59 0.3× 65 0.3× 72 840
Joel David United Kingdom 21 47 0.1× 422 2.1× 157 0.8× 12 0.1× 259 1.4× 63 1.3k
Anne E. Hammer United States 28 40 0.1× 28 0.1× 67 0.3× 233 1.2× 67 0.4× 59 2.1k

Countries citing papers authored by Alex Mercer

Since Specialization
Citations

This map shows the geographic impact of Alex Mercer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Mercer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Mercer more than expected).

Fields of papers citing papers by Alex Mercer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Mercer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Mercer. The network helps show where Alex Mercer may publish in the future.

Co-authorship network of co-authors of Alex Mercer

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Mercer. A scholar is included among the top collaborators of Alex Mercer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Mercer. Alex Mercer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheung, Chee Kay, Stephanie Moody, Neeraj Dhaun, et al.. (2025). WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL. Kidney International Reports. 10(2). S204–S204. 1 indexed citations
2.
Trachtman, Howard, Jai Radhakrishnan, Michelle N. Rheault, et al.. (2024). Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study. Kidney International Reports. 9(4). 1020–1030. 2 indexed citations
3.
Kooienga, Laura, et al.. (2024). Concomitant Sparsentan (SPAR) and SGLT2 Inhibitors in Patients with IgA Nephropathy in the PROTECT Open-Label Extension (OLE). Journal of the American Society of Nephrology. 35(10S). 2 indexed citations
4.
Mercer, Alex, Kevin Carroll, Bruce M. Hendry, et al.. (2023). #4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations
5.
Ayoub, Isabelle, Radko Komers, Alex Mercer, et al.. (2023). Sparsentan and Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in the PROTECT Open-Label Extension (OLE) Substudy and SPARTACUS: Trials in Progress. Journal of the American Society of Nephrology. 34(11S). 979–979. 1 indexed citations
6.
Kooienga, Laura, Robert Małecki, Priscila Preciado, Ping He, & Alex Mercer. (2023). Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE). Journal of the American Society of Nephrology. 34(11S). 979–979. 2 indexed citations
7.
Barratt, Jonathan, Brad H. Rovin, Muh Geot Wong, et al.. (2023). IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study. Kidney International Reports. 8(5). 1043–1056. 20 indexed citations
8.
Barratt, Jonathan, Hiddo J.L. Heerspink, Muh Geot Wong, et al.. (2023). #4057 SUPERIOR PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): A PROTECT STUDY INTERIM ANALYSIS. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations
9.
Inker, Lesley A., Hiddo J.L. Heerspink, Hocine Tighiouart, et al.. (2021). Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases. 78(3). 340–349.e1. 45 indexed citations
10.
Barratt, Jonathan, Brad H. Rovin, Ulysses Diva, Alex Mercer, & Radko Komers. (2019). Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial). Kidney International Reports. 4(11). 1633–1637. 23 indexed citations
11.
Thompson, Aliza, Kevin Carroll, Lesley A. Inker, et al.. (2019). Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 14(3). 469–481. 161 indexed citations
12.
Fellström, Bengt, Jonathan Barratt, H. Terence Cook, et al.. (2017). Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. The Lancet. 389(10084). 2117–2127. 254 indexed citations
13.
Inker, Lesley A., Tom Greene, Francesco Locatelli, et al.. (2016). Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. American Journal of Kidney Diseases. 68(3). 392–401. 94 indexed citations
14.
Bertilsson, Göran, Cesare Patrone, Olof Zachrisson, et al.. (2007). Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease. Journal of Neuroscience Research. 86(2). 326–338. 298 indexed citations
15.
Mercer, Alex, et al.. (2006). Validating Neonatal Mortality and Use of NGO Reproductive Health Outreach Services in Rural Bangladesh. Studies in Family Planning. 37(2). 111–122. 14 indexed citations
16.
Mercer, Alex, et al.. (2005). Use of Family Planning Services in the Transition To a Static Clinic System in Bangladesh: 1998–2002. International Family Planning Perspectives. 31(3). 115–123. 10 indexed citations
17.
18.
Wirta, Valtteri, Alex Mercer, Konstantinos Meletis, et al.. (2005). Transcriptome analysis in primary neural stem cells using a tag cDNA amplification method. BMC Neuroscience. 6(1). 28–28. 10 indexed citations
19.
Mercer, Alex, Harriet Rönnholm, Johan Holmberg, et al.. (2004). PACAP promotes neural stem cell proliferation in adult mouse brain. Journal of Neuroscience Research. 76(2). 205–215. 81 indexed citations
20.
Wikström, Lilian & Alex Mercer. (2001). Stem Cells and CNS Development. Drug Discovery Today. 6(22). 1152–1152. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Denis Morin Breakdown of academic impact, for papers by Susan Ritchie Breakdown of academic impact, for papers by Alison Skrinar Breakdown of academic impact, for papers by Gary Milligan Breakdown of academic impact, for papers by Cheng-Chun Lee Breakdown of academic impact, for papers by Stephanie Krämer Breakdown of academic impact, for papers by Janet Y. Lee Breakdown of academic impact, for papers by Jia‐Shu Chen Breakdown of academic impact, for papers by Joel David Breakdown of academic impact, for papers by Anne E. Hammer
Rankless by CCL
2026